Prostaglandin I2 and E2 mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury

Hepatology

Volumn 45, Issue 1, 2007, Pages 159-169

  Yin, Hao ^a   Cheng, Linling ^a   Langenbach, Robert ^b   Ju, Cynthia ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; CASPASE 3; CONCANAVALIN A; CYCLOOXYGENASE 2; GAMMA INTERFERON; MISOPROSTOL; PROSTACYCLIN; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; HEPATITIS; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LIVER INJURY; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CONCANAVALIN A; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EPOPROSTENOL; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION; INTERFERON TYPE II; LIVER DISEASES; MALE; MICE; MICE, KNOCKOUT; MISOPROSTOL; MITOGENS;

EID: 33846447035     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21493     Document Type: Article

References (48)

1. Tiegs G, Hentsehel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992;90:196-203.
2. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 2000;97:5498-5503.
3. Schumann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N, et al. Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 2000;157:1671-1683.
4. Kusters S, Gantner F, Kunstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996;111:462-471.
5. Nicoletti F, Zaccone P, Xiang M, Magro G, Di Mauro M, Di Marco R, et al. Essential pathogenetic role for interferon (IFN-)gamma in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein. Cytokine 2000;12:315-323.
6. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. HEPATOLOGY 1995;21:190-198.
7. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994;179:1529-1537.
8. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-492.
9. Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann N Y Acad Sci 1999;889:52-61.
10. Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham SG, Shlopov BV, et al. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum 2000;43:2687-2693.
11. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-182.
12. Gilroy DW, Colville-Nash PR. New insights into the role of COX 2 in inflammation. J Mol Med 2000;78:121-129.
13. Andrade RJ, Lucena MI, Fernandez MC, Gonzalez M. Fatal hepatitis associated with nimesulide. J Hepatol 2000;32:174.
14. Galan MV, Gordon SC, Silverman AL. Celecoxib-induced cholestatic hepatitis. Ann Intern Med 2001;134:254.
15. McCormick PA, Kennedy F, Curry M, Traynor O. COX 2 inhibitor and fulminant hepatic failure. Lancet 1999;353:40-41.
16. Stadimann S, Zoller H, Vogel W, Offner FA. COX-2 inhibitor (nimesulide) induced acute liver failure. Virchows Arch 2002;440:553-555.
17. Van Steenbergen W, Peeters P, De Bondt J, Staessen D, Buscher H, Laporta T, et al. Nimesulide-induced acute hepatitis: evidence from six cases. J Hepatol 1998;29:135-141.
18. Quiroga J, Prieto J. Liver cytoprotection by prostaglandins. Pharmacol Ther 1993;58:67-91.
19. Jugdutt BI. Prostaglandins in myocardial: with emphasis on myocardial preservation. Prostaglandins Med 1981;7:109-123.
20. Moncada S, Vane JR. The role of prostacyclin in vascular tissue. Fed Proc 1979;38:66-71.
21. Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation. 2000;102:426-431.
22. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502.
23. Kato H, Takashima T, Kishikawa H, Emura S, Ohmori K. Effect of beraprost sodium, a stable prostaglandin 12 analogue, on platelet aggregation in diabetes mellitus. Int J Clin Pharmacol Res 1996;16:99-102.
24. Goto S, Kim YI, Kawano K, Kai T, Kobayashi M. Efficacy of PGI2 analog in preventing ischemia reperfusion damage of liver grafts from living donors. Transpl Int. 1992;(5 Suppl 1):S366-S369.
25. Ohta S, Nakamuta M, Fukushima M, Kohjima M, Kotoh K, Enjoji M, et al. Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates concanavalin A-induced liver injury in mice. Liver Int 2005;25:1061-1068.
26. Griffiths R. Inflammation: Basic Principles and Clinical Correlates. Philadelphia, PA: Lippincott Williams & Wilkins, 1999.
27. Jaworek J, Bonior J, Tomaszewska R, Jachimczak B, Kot M, Bielanski W, et al. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide. J Physiol Pharmacol 2001;52:107-126.
28. Flisiak R, Prokopowicz D. One year follow-up of patients treated with misoprostol in acute phase of viral hepatitis B. Prostaglandins Other Lipid Mediat 2000;60:161-165.
29. Gavett SH, Madison SL, Chulada PC, Scarborough PE, Qu W, Boyle JE, et al. Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 1999;104:721-732.
30. Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004;127:1760-1774.
31. Franklin CC, Krejsa CM, Pierce RH, White CC, Fausto N, Kavanagh TJ. Caspase-3-dependent cleavage of the glutamate-L-cysteine ligase catalytic subunit during apoptotic cell death. Am J Pathol 2002;160:1887-1894.
32. Warschkau H, Kiderlen AF. A monoclonal antibody directed against the murine macrophage surface molecule F4/80 modulates natural immune response to Listeria monocytogenes. J Immunol 1999;163:3409-3416.
33. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-411.
34. Ding JW, Wang K, Brems JJ, Gamelli RL. Protection against concanavalin A-induced hepatocyte apoptosis by molsidomine is time-dependent. J Am Coll Surg 2004;198:67-77.
35. Kim KM, Kim YM, Park M, Park K, Chang HK, Park TK, et al. A broad-spectrum caspase inhibitor blocks concanavalin A-induced hepatitis in mice. Clin Immunol. 2000;97:221-233.
36. Segawa Y, Itokazu Y, Inoue N, Saito T, Suzuki K. Possible changes in expression of chemotaxin LECT2 mRNA in mouse liver after concanavalin A-induced hepatic injury. Biol Pharm Bull 2001;24:425-428.
37. Reilly TP, Brady JN, Marchick MR, Bourdi M, George JW, Radonovich MF, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001;14:1620-1628.
38. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-409.
39. Tagawa Y, Sekikawa K, Iwakura Y. Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J Immunol. 1997;159:1418-1428.
40. Kennedy MS, Stobo JD, Goldyne ME. In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. Prostaglandins 1980;20:135-145.
41. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001;108:15-23.
42. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103:147-166.
43. Chen CH, Lin H, Hsu YH, Sue YM, Cheng TH, Chan P, et al. The protective effect of prostacyclin on adriamycin-induced apoptosis in rat renal tubular cells. Eur J Pharmacol 2006;529:8-15.
44. Ishaque A, Dunn MJ, Sorokin A. Cyclooxygenase-2 inhibits tumor necrosis factor alpha-mediated apoptosis in renal glomerular mesangial cells. J Biol Chem 2003;278:10629-10640.
45. Yano T, Itoh Y, Kubota T, Sendo T, Koyama T, Fujita T, et al. A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am J Pathol 2005;166: 1333-1342.
46. Sulica R, Emre S, Poon M. Medical management of porto-pulmonary hypertension and right heart failure prior to living-related liver transplantation. Congest Heart Fail 2004;10:192-194.
47. Uchiyama H, Soejima Y, Taketomi A, Yoshizumi T, Harada N, Ijichi H, et al. Successful adult-to-adult living donor liver transplantation in a patient with moderate to severe portopulmonary hypertension. Liver Transpl 2006;12:481-484.
48. Shield MJ. Novel applications of misoprostol. Pharmacol Ther 1995;65: 125-147.